# The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

> **NCT05213884** · PHASE2 · COMPLETED · sponsor: **Chongqing University Cancer Hospital** · enrollment: 39 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Concurrent cisplatin chemotherapy
- **RADIATION:** Intensity-modulated radiotherapy (IMRT)

## Key facts

- **NCT ID:** NCT05213884
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2026-02-08
- **Final completion:** 2026-02-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213884, "The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05213884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*